JP6903633B2 - 腫瘍抑制ペプチド - Google Patents

腫瘍抑制ペプチド Download PDF

Info

Publication number
JP6903633B2
JP6903633B2 JP2018504942A JP2018504942A JP6903633B2 JP 6903633 B2 JP6903633 B2 JP 6903633B2 JP 2018504942 A JP2018504942 A JP 2018504942A JP 2018504942 A JP2018504942 A JP 2018504942A JP 6903633 B2 JP6903633 B2 JP 6903633B2
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
seq
acid residue
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018504942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526987A5 (enExample
JP2018526987A (ja
Inventor
宏 利 劉
宏 利 劉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Bio Pharma Tech Co Ltd
Original Assignee
G Bio Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Bio Pharma Tech Co Ltd filed Critical G Bio Pharma Tech Co Ltd
Publication of JP2018526987A publication Critical patent/JP2018526987A/ja
Publication of JP2018526987A5 publication Critical patent/JP2018526987A5/ja
Application granted granted Critical
Publication of JP6903633B2 publication Critical patent/JP6903633B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018504942A 2015-07-27 2016-07-21 腫瘍抑制ペプチド Active JP6903633B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510446747.4 2015-07-27
CN201510446747 2015-07-27
PCT/CN2016/090800 WO2017016430A1 (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Publications (3)

Publication Number Publication Date
JP2018526987A JP2018526987A (ja) 2018-09-20
JP2018526987A5 JP2018526987A5 (enExample) 2019-08-08
JP6903633B2 true JP6903633B2 (ja) 2021-07-14

Family

ID=57883958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504942A Active JP6903633B2 (ja) 2015-07-27 2016-07-21 腫瘍抑制ペプチド

Country Status (5)

Country Link
US (1) US10351613B2 (enExample)
EP (1) EP3330285B1 (enExample)
JP (1) JP6903633B2 (enExample)
CN (17) CN113943363B (enExample)
WO (1) WO2017016430A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113943363B (zh) * 2015-07-27 2023-11-28 上海贺普药业股份有限公司 一种肿瘤抑制肽
CN113244370A (zh) * 2020-02-13 2021-08-13 珠海市藤栢医药有限公司 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
CN115991739B (zh) * 2021-12-20 2023-10-20 珠海市藤栢医药有限公司 一种抗肿瘤的多肽及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
CN1239516C (zh) * 2002-02-08 2006-02-01 中国医学科学院基础医学研究所 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途
WO2003074551A2 (en) * 2002-03-01 2003-09-12 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US7078485B2 (en) * 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
CN1875104A (zh) * 2003-08-29 2006-12-06 儿童医学中心公司 来自内皮抑素n－末端的抗血管生成肽
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
JP2007529410A (ja) * 2003-08-29 2007-10-25 チルドレンズ メディカル センター コーポレーション 子宮内膜症を治療又は防止するためのペプチド
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CN101062954A (zh) * 2006-05-16 2007-10-31 中国人民解放军军事医学科学院野战输血研究所 具有抗血管生成作用的融合蛋白及其编码基因与应用
CN100586961C (zh) * 2006-05-16 2010-02-03 中国人民解放军军事医学科学院野战输血研究所 对肿瘤细胞具有抑制作用的融合蛋白及其编码基因与应用
WO2008125635A1 (en) * 2007-04-11 2008-10-23 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
CN101096671A (zh) * 2007-06-01 2008-01-02 徐寒梅 血管生成抑制剂hm-x及其制备方法和应用
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
CN102924578A (zh) * 2011-08-09 2013-02-13 哈药集团技术中心 抗肿瘤多肽及其制备方法和抗肿瘤应用
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
CN113943363B (zh) * 2015-07-27 2023-11-28 上海贺普药业股份有限公司 一种肿瘤抑制肽

Also Published As

Publication number Publication date
CN115433268A (zh) 2022-12-06
CN113717278A (zh) 2021-11-30
CN114031683A (zh) 2022-02-11
CN115433269B (zh) 2025-10-17
CN115433267A (zh) 2022-12-06
EP3330285A4 (en) 2019-01-09
CN113980120B (zh) 2024-06-04
CN113717277A (zh) 2021-11-30
CN113943364B (zh) 2024-02-02
CN114031683B (zh) 2023-12-26
CN115433269A (zh) 2022-12-06
CN113717275A (zh) 2021-11-30
CN115433270A (zh) 2022-12-06
EP3330285A1 (en) 2018-06-06
JP2018526987A (ja) 2018-09-20
CN113943363B (zh) 2023-11-28
CN113717275B (zh) 2024-02-02
CN113717278B (zh) 2024-02-02
CN107922475B (zh) 2021-08-27
CN115433268B (zh) 2025-10-03
CN113943365A (zh) 2022-01-18
CN107922475A (zh) 2018-04-17
CN113980119B (zh) 2024-05-28
CN115433270B (zh) 2025-10-14
US20190010201A1 (en) 2019-01-10
CN113943363A (zh) 2022-01-18
CN113943364A (zh) 2022-01-18
CN113980119A (zh) 2022-01-28
EP3330285B1 (en) 2022-08-31
CN113717274B (zh) 2023-11-28
CN113980120A (zh) 2022-01-28
WO2017016430A1 (zh) 2017-02-02
CN113912705B (zh) 2023-12-22
US10351613B2 (en) 2019-07-16
CN113717274A (zh) 2021-11-30
CN113717277B (zh) 2024-02-02
CN113717276B (zh) 2024-02-02
CN113717276A (zh) 2021-11-30
CN113912705A (zh) 2022-01-11
CN113943365B (zh) 2023-12-08

Similar Documents

Publication Publication Date Title
JP6903633B2 (ja) 腫瘍抑制ペプチド
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
CN108295244B (zh) 用于治疗乳腺肿瘤的多肽
CN108299556A (zh) 一种治疗血液肿瘤的多肽
CN101112358B (zh) 葡激酶肌肉注射剂及其制备方法
JP2018507854A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210623

R150 Certificate of patent or registration of utility model

Ref document number: 6903633

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250